Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 288Breast Neoplasms 285Lung Neoplasms 136Prostatic Neoplasms 126Colorectal Neoplasms 114Carcinoma, Non-Small-Cell Lung 109Pancreatic Neoplasms 73Carcinoma, Hepatocellular 58Stomach Neoplasms 54Hematologic Neoplasms 54Brain Neoplasms 53Ovarian Neoplasms 52Urinary Bladder Neoplasms 50Multiple Myeloma 50Leukemia, Myeloid, Acute 48Esophageal Neoplasms 48Melanoma 47Head and Neck Neoplasms 43Disease 43Colonic Neoplasms 40Rectal Neoplasms 38Liver Neoplasms 38Neoplasm Metastasis 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma 33Uterine Cervical Neoplasms 32Endometrial Neoplasms 32Leukemia, Lymphocytic, Chronic, B-Cell 31Thyroid Neoplasms 30Recurrence 29

Interventions

somapacitan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dwarfism, Pituitary × 90 days × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡